With this morning's news of a licensing deal between AtheroGenics Inc (NASDAQ: AGIX) and AstraZeneca (NYSE: AZN), potentially worth $1 ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE